Tobramycin is a powerful antibiotic medicine used to fight certain types of infections. It's often used to treat infections in the eyes or lungs. It works by killing the bacteria that cause the infection.
Every report comes from a Lived member, sent anonymously.
Have you tried Tobramycin for Cystic Fibrosis?
Tobramycin is a prescription antibiotic from a family called aminoglycosides. It is especially useful against gram-negative bacteria, a category of bacteria in which many resist common antibiotics, including Pseudomonas aeruginosa, a germ that is hard to treat and common in hospital infections and in the lungs of people with cystic fibrosis. The same medicine comes in three quite different forms, and each is used for different reasons. As an injection, tobramycin is used, usually in the hospital, for serious infections such as bloodstream infections, pneumonia, abdominal infections, meningitis, bone and skin infections, and complicated or repeated urinary tract infections. It is often given alongside another antibiotic, and it is not meant for a simple first bladder infection that a gentler antibiotic can treat. As an inhaled medicine, sold as TOBI (a solution for a nebulizer), TOBI Podhaler (a dry powder) and generic versions, it is approved for people aged 6 and older with cystic fibrosis whose lungs are infected with Pseudomonas. Cystic fibrosis care teams also use it to try to clear a newly detected Pseudomonas infection before it settles in. As eye drops or ointment, such as Tobrex and generics, it treats bacterial infections on the surface of the eye and eyelids. TobraDex combines tobramycin with dexamethasone, a steroid, for inflamed eyes where infection is present or likely; the steroid adds its own risks with longer use, such as raised eye pressure, so the eye may need checking.
Bacteria need to make proteins constantly in order to grow and divide. Tobramycin gets inside the bacterial cell and blocks the machinery that builds those proteins, and the bacteria die as a result. Because it kills bacteria rather than just slowing them, it is valuable for serious infections. Tobramycin is barely absorbed from the stomach, which is why it is never taken as a pill. Delivering it by vein, by inhalation or into the eye puts it where the infection is. Inhaling it reaches high levels in the airways while very little enters the bloodstream, which lowers, though does not remove, the risk of the hearing and kidney harm that can come with injections.
Injected tobramycin is given into a vein or muscle, usually for 7 to 10 days, with the dose based on body weight and kidney function. Because the gap between an effective level and a harmful one is narrow, the care team typically measures blood levels: a peak level shortly after a dose to confirm it is high enough to work, and a trough level just before the next dose to make sure the drug is clearing. Kidney blood tests are checked along the way, and doses are adjusted if kidney function changes. Inhaled tobramycin for cystic fibrosis is a fixed dose, not adjusted for weight, taken twice a day, ideally about 12 hours apart and never less than 6 hours apart. It is used in cycles of 28 days on followed by 28 days off, which helps keep it working while limiting resistance. The nebulizer solution should not be mixed with other medicines, such as dornase alfa (Pulmozyme), in the same nebulizer cup. People who use several inhaled treatments or airway clearance should follow their team's order; for TOBI Podhaler, the label recommends taking it last. TOBI Podhaler capsules are inhaled through their own device and must never be swallowed, because they will not work that way. Eye drops are usually used every few hours, more often for severe infections, and then tapered as the eye improves. Finish the course as prescribed.
With inhaled tobramycin, the most noticeable effects are a change in voice or hoarseness and, less often, ringing in the ears. With the nebulizer solution, cough, sore throat and extra mucus are usually part of cystic fibrosis itself rather than the medicine, since in trials they occurred about as often with a placebo. The dry powder (TOBI Podhaler) is different: cough is its most common side effect, happens more often than with the nebulizer solution, and is a common reason people stop it. Some people feel chest tightness or wheezing right after a dose, because the airways can tighten in response to the inhaled medicine; tell the care team promptly, the same day. With eye drops, the usual effects are local: itching or swelling of the lids and redness of the eye. If irritation grows worse or a rash appears, stop the drops and contact the prescriber, since this can be an allergic reaction. The serious risks mainly come with injections and long or repeated courses. Tobramycin can damage the inner ear, causing hearing loss or balance problems that may be permanent and may continue to develop even after treatment ends. Ringing in the ears, muffled hearing, dizziness or unsteadiness should be reported to the care team promptly. It can also harm the kidneys; this is usually reversible and is watched through blood tests, and rarely shows up a few days after the last dose. Numbness, tingling or muscle twitching are less common nerve effects worth reporting.
Anyone with an allergy to tobramycin or another aminoglycoside, such as gentamicin or amikacin, should not use it, because reactions can cross between these drugs. The risk of ear and kidney damage rises when tobramycin is combined with other medicines that strain the same organs. These include other aminoglycosides, vancomycin and colistin (antibiotics for resistant infections), cisplatin (a chemotherapy drug) and strong diuretics, or water pills, such as furosemide (Lasix). Dehydration, older age and existing kidney disease add to the risk. Tobramycin can interfere with the signals between nerves and muscles. It can worsen weakness in people with myasthenia gravis or Parkinson's disease, and can prolong the effect of muscle relaxants used during anesthesia, so surgical teams should know about it. Some people carry an inherited change in their mitochondrial DNA (a variant in the MT-RNR1 gene) that makes them unusually prone to permanent hearing loss from aminoglycosides, even at normal doses. A family history of hearing loss after these antibiotics is worth mentioning before treatment. Aminoglycosides given by injection can harm a developing baby's hearing. Much less reaches the bloodstream from inhaled or eye forms, but anyone pregnant or planning pregnancy should discuss the choice with their prescriber.
In the hospital, injected tobramycin is often started before test results come back and then continued or switched once lab tests show which bacteria are present and which antibiotics they respond to. Expect regular blood draws for drug levels and kidney function. For longer courses or higher-risk patients, a hearing test may be done before and during treatment. For cystic fibrosis, inhaled tobramycin is a long-term maintenance treatment rather than a quick cure. Its practical aim is to keep lung function holding up better and reduce flare-ups, hospital stays and the need for intravenous antibiotics; in the original trials, people using it did better on each of these than those on placebo, with less Pseudomonas in their sputum during on-months. The bacterial count tends to rise again during off-months, and the drop in bacteria was smaller with each successive cycle. Each nebulizer treatment takes about 15 minutes. Some bacteria become less sensitive to tobramycin over years of use, so the team checks sputum cultures regularly. For eye infections, the drops are used often at first and then less often as the eye improves. If the eye is not getting better as expected, or if vision changes or the eye becomes painful, the prescriber should reassess.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Tobramycin, what you've noticed, or ask the community a question.